Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
$10.53
-5.2%
$10.31
$7.80
$28.09
$605.90MN/A309,275 shs409,857 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.12
+3.4%
$1.74
$1.09
$7.22
$145.57M2.971.53 million shs750,601 shs
Organogenesis stock logo
ORGO
Organogenesis
$4.51
-2.4%
$3.81
$2.28
$6.71
$586.06M1.76817,949 shs1.55 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.36
-4.5%
$3.42
$1.77
$10.72
$603.49M1.622.64 million shs2.79 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-5.22%-10.38%+14.46%-27.38%+1,052,999,900.00%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+3.41%-6.19%+39.47%+21.84%-68.36%
Organogenesis stock logo
ORGO
Organogenesis
-2.38%-10.34%+11.36%-14.58%+49.34%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-4.55%-10.16%-6.67%+3.38%-59.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.3838 of 5 stars
3.34.00.00.01.11.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.004 of 5 stars
3.32.00.04.30.64.20.6
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
1.956 of 5 stars
3.40.00.00.02.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3.00
Buy$31.86202.55% Upside
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.50
Moderate Buy$12.00466.04% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.67
Moderate Buy$6.5044.12% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.83
Moderate Buy$17.67425.79% Upside

Current Analyst Ratings Breakdown

Latest CCCC, RLAY, BCAX, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
7/15/2025
Organogenesis stock logo
ORGO
Organogenesis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$8.00
5/23/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
5/16/2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $41.00
5/7/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $10.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/A$9.04 per shareN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M4.23N/AN/A$3.06 per share0.69
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.19$0.20 per share22.14$2.09 per share2.16
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M57.55N/AN/A$4.65 per share0.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%8/7/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/7/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/7/2025 (Estimated)

Latest CCCC, RLAY, BCAX, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.54N/AN/AN/AN/AN/A
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.41N/AN/AN/A$5.24 millionN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01N/AN/AN/A$104.75 millionN/A
8/7/2025Q2 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.49N/AN/AN/A$0.07 millionN/A
5/13/2025Q1 2025
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
-$0.40-$0.68-$0.28-$0.68N/AN/A
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/7/2025Q1 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million
5/5/2025Q1 2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
24.62
24.62
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.70
5.70
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
19.96
19.96

Institutional Ownership

CompanyInstitutional Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
N/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
15.50%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bicara Therapeutics Inc. stock logo
BCAX
Bicara Therapeutics
3254.54 million46.08 millionN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.01 million64.81 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330171.45 million163.10 millionOptionable

Recent News About These Companies

Relay Therapeutics, Inc. (RLAY) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bicara Therapeutics stock logo

Bicara Therapeutics NASDAQ:BCAX

$10.53 -0.58 (-5.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.05 -0.48 (-4.56%)
As of 08/1/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.12 +0.07 (+3.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.16 +0.04 (+1.89%)
As of 08/1/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.51 -0.11 (-2.38%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.51 +0.00 (+0.11%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.36 -0.16 (-4.55%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.36 0.00 (0.00%)
As of 08/1/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.